Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,209
Open 66.30
Bid (Size) 65.45 (14)
Ask (Size) 65.48 (1)
Prev. Close 66.30
Today's Range 66.30 - 66.30
52wk Range 53.63 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
+13.70%
+13.70%
1 Month
-0.66%
-0.66%
3 Month
+7.93%
+7.93%
6 Month
+15.91%
+15.91%
1 Year
+17.51%
+17.51%

More News

Read More
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Via Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Avalo Therapeutics, Apollo Therapeutics Ink Pact For Anti-IL-18 Antibody
Via Benzinga
Lyme Disease And Climate Change Reinvigorates Valneva's Vaccine Efforts After COVID Shot Disappointment
Via Benzinga
The Power of Science to Stop a Killer
Via Investor Brand Network
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
Via Benzinga
The Power of Science to Stop a Killer
Via FinancialNewsMedia
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
Via Benzinga
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
From AstraZeneca
Via Business Wire
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
From AstraZeneca
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
Via Benzinga
AstraZeneca and Merck Receives European Commission Approval For Expanded Use In Breast Cancer Therapy
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
3 Pharma Stocks' Post-Earnings Price Moves
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Via Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
Via Benzinga
3-D Portfolio: Discounts, Diversification, And Dividends
Via Talk Markets
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.